Published in Semin Intervent Radiol on December 01, 2015
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Hepatocellular carcinoma. Lancet (2003) 22.54
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology (2005) 3.63
Loco-regional treatment of hepatocellular carcinoma. Hepatology (2010) 3.59
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology (1997) 3.28
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology (2011) 3.26
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant (2009) 3.09
Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (2002) 3.00
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg (2007) 2.40
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol (2008) 2.36
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg (2000) 2.32
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology (2013) 2.30
Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol (2009) 2.27
Outpatient single-session yttrium-90 glass microsphere radioembolization. J Vasc Interv Radiol (2013) 2.16
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
RADIATION HEPATITIS. Am J Roentgenol Radium Ther Nucl Med (1965) 2.14
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev (2010) 2.09
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol (2006) 1.64
Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol (2010) 1.62
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology (2004) 1.57
Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging (2010) 1.51
Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol (2014) 1.50
Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. J Vasc Interv Radiol (2013) 1.48
Portal vein occlusion prior to extensive resection in colorectal liver metastasis: a necessity rather than an option! Ann Surg Oncol (2009) 1.46
Portal vein embolization before right hepatectomy or extended right hepatectomy using sodium tetradecyl sulfate foam: technique and initial results. J Vasc Interv Radiol (2014) 1.41
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med (2012) 1.39
Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med (2010) 1.30
Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology (2005) 1.27
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology (2013) 1.23
Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol (2009) 1.23
Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology (2013) 1.21
Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol (2009) 1.17
Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer (2009) 1.10
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol (2013) 1.08
Tumor progression after preoperative portal vein embolization. Ann Surg (2012) 1.07
The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol (2009) 1.06
Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol (2009) 1.02
Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol (2013) 1.02
Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol (2013) 1.00
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging (2013) 0.99
Combination of intra-arterial therapies and sorafenib: is there a clinical benefit? Radiol Med (2014) 0.96
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology (2013) 0.95
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One (2014) 0.91
Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol (2005) 0.91
Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol (2011) 0.90
Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant (2008) 0.89
Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 0.84
Enhanced tumor growth after portal vein embolization in a rabbit tumor model. J Surg Res (2012) 0.82
Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization? Eur J Radiol (2012) 0.81
Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol (2014) 0.80
Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting. Radiology (2014) 0.79
Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vasc Interv Radiol (2013) 0.78